ArticleAmerican journal of blood research2026
Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients.
Article in American journal of blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood acute myeloid leukemia (AML) comprises 15-20% of pediatric leukemias and carries promising survival rates (60-70%) in high-income countries with use of intensive chemotherapy. This is associated with high treatment-related mortality in low- and middle-income countries, especially during induction, due to malnutrition, infections, and insufficient resources. Venetoclax, a BCL-2 inhibitor effective in older adults unfit for standard therapy, has shown potential in pediatric relapse AML. Here, we describe two children with newly diagnosed AML who developed life-threatening toxicities with intensive chemotherapy and were subsequently treated with venetoclax-based low-intensity regimens. Both patients achieved complete remission, attained measurable residual disease negativity, and maintained durable responses with minimal toxicity, allowing largely outpatient management. These cases suggest a promising, feasible alternative for chemotherapy-intolerant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.